Phase II trial of sorafenib (bay 43-9006) in patients with advanced anaplastic carcinoma of the thyroid (ATC)

被引：0
|
作者：
Nagaiah, G.
Fu, P.
Wasman, J. K.
Cooney, M. M.
Mooney, C.
Afshin, D.
Lavertu, P.
Bokar, J.
Savvides, P.
Remick, S. C.
机构：
[1] Univ Hosp Case Med Ctr, Cleveland, OH USA
[2] Case Western Reserve Univ, Cleveland, OH 44106 USA
[3] Univ Michigan, Ann Arbor, MI 48109 USA
[4] W Virginia Univ, Morgantown, WV 26506 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2009年 / 27卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6058
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Results of a Phase I trial of sorafenib (BAY 43-9006) in combination with doxorubicin in patients with refractory solid tumors
    Richly, H
    Henning, BF
    Kupsch, P
    Passarge, K
    Grubert, M
    Hilger, RA
    Christensen, O
    Brendel, E
    Schwartz, B
    Ludwig, M
    Flashar, C
    Voigtmann, R
    Scheulen, ME
    Seeber, S
    Strumberg, D
    ANNALS OF ONCOLOGY, 2006, 17 (05) : 866 - 873
  • [22] Final findings from a phase II, placebo-controlled, randomized discontinuation trial (RDT) of sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC).
    Ratain, MJ
    Eisen, T
    Stadler, WM
    Flaherty, KT
    Gore, M
    Desai, A
    Patnaik, A
    Xiong, HQ
    Schwartz, B
    O'Dwyer, P
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 388S - 388S
  • [23] A phase I trial of sorafenib (BAY 43-9006) for patients with recurrent or progressive malignant glioma (NABTT 0401)
    Nabors, L. B.
    Rosenfeld, M.
    Chamberlain, M.
    Phuphanich, S.
    Batchelor, T.
    Supko, J.
    Desideri, S.
    Xiaobu, Y.
    Wright, J.
    Grossman, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [24] A phase II study of BAY 43-9006 (sorafenib) in patients with androgen-independent prostate cancer (AlPC)
    Dahut, W.
    Posadas, E.
    Scripture, C.
    Gulley, J.
    Arlen, P.
    Wright, J.
    Harold, N.
    Fioravanti, S.
    Figg, W.
    EJC SUPPLEMENTS, 2005, 3 (02): : 248 - 248
  • [25] A phase II multicenter uncontrolled trial of single agent sorafenib (BAY 43-9006) in patients with relapsed or refractory advanced non-small-cell lung carcinoma.
    Blumenschein, GR
    Gatzemeier, U
    Fossella, F
    Burk, K
    Reck, M
    CLINICAL CANCER RESEARCH, 2005, 11 (24) : 9120S - 9120S
  • [26] Randomised phase-III-study of the multi-kinase inhibitors Sorafenib (BAY 43-9006) for patients with advanced renal cell carcinoma
    Staehler, M.
    Siebels, M.
    Stief, C.
    Jaeger, E.
    Heinzer, H.
    Grimm, M. -O.
    Gschwend, J.
    Wirth, M.
    Michell, M. -S.
    Rohde, D.
    Krause, S.
    Siegsmund, M.
    Scheuring, U.
    Schwartz, B.
    Escudier, B.
    ONKOLOGE, 2007, 13 : 18 - 19
  • [27] Phase II study of BAY 43-9006 (sorafenib) in patients with chemo-naive hormone refractory prostate cancer
    Akyol, F.
    Ozyigit, G.
    Selek, U.
    Onal, C.
    Karabulut, E.
    Ozen, H.
    EJC SUPPLEMENTS, 2005, 3 (02): : 248 - 249
  • [28] Phase II trial of sorafenib for advanced or metastatic medullary thyroid carcinoma and anaplastic thyroid carcinoma
    Ito, Ken-ichi
    ANNALS OF ONCOLOGY, 2016, 27
  • [29] Phase II study of sorafenib (BAY 43-9006) in combination with gemcitabine in recurrent epithelial ovarian cancer: A PMH phase II consortium trial.
    Welch, S.
    Hirte, H.
    Schilder, R. J.
    Elit, L.
    Townsley, C.
    Tinker, L.
    Pond, G.
    Afinec, A.
    Wright, J. J.
    Oza, A. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 276S - 276S
  • [30] Phase I/II, pharmacokinetic and pharmacodynamic trial of BAY 43-9006 alone in patients with metastatic melanoma.
    Flaherty, KT
    Redlinger, M
    Schuchter, LM
    Lathia, CD
    Weber, BL
    O'Dwyer, PJ
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 201S - 201S
12345